Navigation Links
MonoSol Rx Completes Thin Film Ondansetron Pilot Bioequivalence Study
Date:2/21/2008

WARREN, N.J., Feb. 21 /PRNewswire/ -- MonoSol Rx, a drug delivery company specializing in dissolving thin film pharmaceutical products, today announced that it has successfully completed a pilot clinical study for its thin film formulation of ondansetron, a selective 5-HT3 receptor antagonist used in the prevention and treatment of nausea and vomiting.

MonoSol Rx's thin film formulation of ondansetron was studied against GlaxoSmithKline's Zofran ODT(R) product. Based on the results of the study, MonoSol Rx is moving immediately to pivotal trials to enable drug submissions both in the US and Europe. The Company expects to file with the appropriate regulatory authorities in 2008.

A. Mark Schobel, president and chief executive officer of MonoSol Rx, stated, "Successful completion of this pilot study marks an important step towards commercializing what we believe is a product with significant benefits over existing formulations of ondansetron. Our thin film formulation of ondansetron is particularly well suited for the target patient population because individuals who are prescribed the drug often have difficulty swallowing due to extreme nausea caused by chemotherapy, radiotherapy and surgical procedures. Incorporating ondansetron into a great-tasting thin film formulation that dissolves quickly in the mouth allows the drug to be easily administered without water, making it more palatable and less likely to cause additional discomfort."

MonoSol Rx's formulation of ondansetron is a new oral formulation expected to be introduced to the market next year. Its indications are the prevention of Chemotherapy-Induced Nausea and Vomiting (CINV), prevention of nausea and vomiting associated with radiotherapy, and prevention of Post-Operative Nausea and Vomiting (PONV).

MonoSol Rx's thin film technology utilizes strategic and proprietary intellectual property that ensures predictable in-vivo performance and provides superior characteristics over
'/>"/>

SOURCE MonoSol Rx
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
6. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
7. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
8. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
9. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
10. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
11. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)...Fla., Dec. 2 Jupiter M...dvanced diagnostic tools available into its imagin...GE Healthcare. The system delivers highly detailed...tter resolution and unique applications, including...aging for patients with renal dysfunction. This r...
(Date:12/2/2009)...ANGELES, December 2 Foun...day that it would initiate a programme of,regular ...the significant,progress which Fountain is making ... to provide shareholders with regular updates on t...rtners and others. , Fountain reports tha...
(Date:12/2/2009)...ec. 2 With the addition of a Manha...Neil H. Ekblom, LeClairRyan,s medical malpractice ...ch in the New York market. Mr. Ekblom, a former st...nding ophthalmology-related malpractice claims. ,... medical malpractice defense attorneys located in ...
Breaking Medicine Technology:Jupiter Medical Center Announces New High-Definition MRI System 2Fountain Healthy Aging Inc Business Update For Shareholders 2Fountain Healthy Aging Inc Business Update For Shareholders 3Neil H. Ekblom and Medical Malpractice Defense Team Join LeClairRyan 2Neil H. Ekblom and Medical Malpractice Defense Team Join LeClairRyan 3K State biologist to further study of cellular process that plays role in chronic disease 57773 1Junk DNA may prove invaluable in quest for gene therapies 57771 1LLNL technology cleans up Visalia Superfund 100 years ahead of schedule 9997 1LLNL technology cleans up Visalia Superfund 100 years ahead of schedule 9997 2LLNL technology cleans up Visalia Superfund 100 years ahead of schedule 9997 3
...Rockwell Medical,Technologies, Inc. (Nasdaq: RMTI...er of concentrates and specialty pharmaceuticals f...D), announced today that it has begun dosing,patie...or Soluble Ferric,Pyrophosphate (SFP), the Company...he Phase IIb Clinical Design is a double-blind, mu...
...ol Shown to Be Safe and Effective for Menopausal ...EACH, Fla., Oct. 3 A study presented today,at the...se Society (NAMS),revealed that Divigel(R) (estrad...and severity of moderate to severe hot flashes ass...at the meeting found that Divigel(R),is a safe and...
Other Medicine Technology:Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study 2Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study 3Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study 4New Data Reveal Topical Divigel(R) (estradiol gel) 0.1% Significantly Reduces Frequency and Severity of Hot Flashes 2
(Date:12/2/2009)...AJoseph Balboni loves sports. An avid tennis playe...-old insurance agent became increasingly frustrate...nus, a degenerative eye disorder. Unable to return..., he faced the prospect of a corneal transplant to...e years ago, Balboni discovered an alternative tre...
(Date:12/2/2009)...009 is the official congress of the European Assoc...nch of the European Society of Cardiology, where t...be presented. , New case reports will be presen...nce highlighting the role of this new technology. ...echniques, it is likely that non-invasive imaging ...
(Date:12/2/2009)... National Pen ( www.pens.com ), a wor...unced today it is giving away 10,000 free business...ember 2, 2009 -- National Pen ( www.pens.com ), a ...nounced today it is giving away 10,000 free busine...o promote business that no other company in the in...
(Date:12/2/2009)... Revolutionary new cell phones that d...rs will be available in early 2010 from Aerius Int...) December 2, 2009 -- Revolutionary new cell phone...from users will be available in early 2010 from Ae...y honored with a Green Technology Award in wireles...
(Date:12/2/2009)... On Sunday, more than 900 runners and...l cross the finish line at the Rock ‘n&rsquo...om, raising over $3.2 million for the Crohn,s &...ining program, Team Challenge (www.ccteamchallenge...will go toward research, education, and support in...
Breaking Medicine News(10 mins):Health News:Brandeis studies evaluate visionary approach to improving eyesight 2Health News:Media alert: EUROECHO 2009 2Health News:National Pen Giving Away 10,000 Business Card Pens 2Health News:New AERIUS Cell Phones Direct Microwave Signals Away from Users 2Health News:Raising Millions for Team Challenge through Rock ‘n' Roll Las Vegas Half Marathon Program Brings Hundreds From Across the Country to Raise Funds for Crohn's & Colitis 2Health News:Raising Millions for Team Challenge through Rock ‘n' Roll Las Vegas Half Marathon Program Brings Hundreds From Across the Country to Raise Funds for Crohn's & Colitis 3Health News:Raising Millions for Team Challenge through Rock ‘n' Roll Las Vegas Half Marathon Program Brings Hundreds From Across the Country to Raise Funds for Crohn's & Colitis 4
...sity researchers seem to know what makes certain b... Colleagues from Edinburgh University and th... closed in on the possible risk factors in prematu...s division, are team leaders of a research group t...
...ned itself many accolades for promoting good healt...t taste in diabetics' mouth. Researchers f...at applying honey on diabetic ulcers could heal th...ique therapy to about 6 diabetic patients. The the...
...sive therapy (ECT) helps patients with severe depr...should be considered more often in the earlier sta...e Southern Medical Journal. "Electroconvul... schizophrenia," writes Dr. Stephen Taylor of the ...
...ve reported the creation of the cells that help bu...have been derived from human embryonic stem cells... These cells have shown promise in lab animal...of these precursor cells, known as "hemangioblast...
...of government allopathic doctors in the country ar...imary Health Centres (PHCs) in position in rural a...rs of beds available in the rural government hospi...% of CHCs are located in government buildings. As ...
... Democratic Front (LDF) government, set to mark it...hat it is to blame for the deaths of 38 newborns i...acted infection in the labour room of the Sree Avi...e not amounting to murder over the deaths. A speci...
Other Medicine News:Health News:Despite Being Effective Electroconvulsive Therapy is Underused for Severe Depression 2
CLEARBLUE EASY OVULATION TEST
Achieva CV
ResMed AutoSet Spirit
BD Vacutainer® Safety-Lok™ Blood Collection Set with Pre Attached Holder
Medicine Products: